Pace Ventures

VC Berlin, Germany · Founded 2022

Pace Ventures is an early-stage venture capital firm that partners with founders tackling critical, overlooked challenges in human health and climate tech across Europe and the United States.

About Pace Ventures

Pace Ventures is a smaller venture firm with website and LinkedIn presence but no disclosed healthcare thesis, sub-vertical focus, AI angle, stage preference, geography or check size in the source data. Founders should treat Pace as a generalist early-stage candidate where domain depth in healthcare is unverified. Plausible check sizes for a firm of this profile sit in the $250K to $1.5M range as a participant in seed and pre-seed rounds, with limited capacity to lead competitive rounds at scale. Pace is most plausibly a fit for digital health, healthcare IT, wellness and consumer-health businesses where general venture pattern-matching is sufficient and the founder owns the clinical and regulatory narrative. Therapeutics, regulated devices, diagnostics and capital-intensive plays are unlikely strong fits. Healthcare AI founders should expect to lead conversations on data strategy, FDA risk if relevant, and realistic sales cycles into hospitals and payers. The firm’s name suggests a thesis around speed, founder velocity or rapid market development, which can be a legitimate edge for the right team but is not confirmed in the source data. Entry is realistic via direct LinkedIn outreach to firm principals, ideally warmed by a mutual investor or portfolio founder, with a tight pitch leading on team strength, traction velocity and capital efficiency. In a first conversation, founders should push for fund size, average check, lead capacity, healthcare exposure in the existing portfolio, and the named partner who would champion a healthcare deal before investing significant cycles.

Founder reviews

No founder reviews yet. Raised from this fund? Share your experience with other founders.

Healthcare AI tools backed by Pace Ventures

Tools made by companies in Pace Ventures's portfolio that we cover in the directory.

Sepsis ImmunoScore
Prenosis
Clinical Decision Support & Reference
Sepsis ImmunoScore by Prenosis is the first FDA-authorized AI diagnostic for sepsis, providing rapid risk assessment and prediction of adverse outcomes. It analyzes 22 parameters from EHRs to generate a risk score and four risk categories, aiding clinicians in faster treatment decisions and improved patient outcomes.

Portfolio companies in our directory

Other portfolio companies

Companies in Pace Ventures's portfolio not currently in our directory.

Team

Marius Swart
General Partner
Gabriel Mu00e9haignerie
Analyst
Luka Niu0107in
Analyst

Pitch / review this investor

Have you raised from Pace Ventures? Founders only — share your honest experience (anonymous OK, moderated before publishing).

Share your experience
Last updated 2026-05-06. Sourced from this fund's published materials.
AI Tool Finder
AI-powered search. Results may not be comprehensive.